News

News and Press Releases
Our Research Approach CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF

ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF. 

| 2 min read
Diversity, Equity, and Inclusion | Our Research Approach CF Foundation Awards Advance Improvements in CF Newborn Screening

Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.

| 4 min read
Our Research Approach CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy

The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.

| 3 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nosis Bio for Potential Gene Therapy Delivery Technology

Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung. 

| 3 min read
Our Research Approach CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug

The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy

Funding will support clinical trials for therapy that could help improve digestion in people with CF

| 3 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nanite Inc. to Explore a New Method to Deliver Genetic Therapies to the Lung

Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.

| 2 min read
Our Research Approach CF Foundation Invests Up to $15M in ReCode Therapeutics for Development of mRNA Therapy

Funding will support preclinical research and early-stage clinical trials

| 3 min read
Our Research Approach CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method

The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.

| 2 min read